Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ImmuPharma ( (GB:IMM) ) has shared an update.
ImmuPharma PLC has appointed Ketan Patel as an independent Non-Executive Director to its Board. Patel brings extensive expertise in financial markets, particularly in the UK healthcare and life science sectors, which will aid ImmuPharma in forming strategic partnerships and expanding its institutional shareholder base. This appointment is expected to enhance the company’s strategic positioning and operational focus, especially concerning its lead auto-immune platform technology, P140.
More about ImmuPharma
ImmuPharma PLC is a specialty biopharmaceutical company focused on discovering and developing peptide-based therapeutics. The company’s portfolio includes novel peptide therapeutics aimed at treating autoimmune diseases and anti-infectives.
Average Trading Volume: 11,445,443
Technical Sentiment Signal: Buy
Current Market Cap: £55.8M
Find detailed analytics on IMM stock on TipRanks’ Stock Analysis page.